{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-23-000046","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.258229+00:00","generated_at":"2026-06-12T09:04:49.755982+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immuneering Q2 net loss $12.2M; cash runway extended into 2025; IMM-1-104 Phase 1b enrolling","bullets":["Net loss of $12.2M ($0.43 per share) vs $11.5M ($0.44 per share) in Q2 2022.","Cash and equivalents $109.0M at June 30, 2023; expects cash runway into 2025.","Completed $30M underwritten offering of 2.73M shares at $11.00 in April 2023.","IMM-1-104 Phase 1a dose escalation completed with no dose-limiting toxicities; Phase 1b enrolling at 240mg or 320mg daily.","RP2D expected early 2024; IND filing for IMM-6-415 expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-23-000046","json":"https://secwatch.observer/filing/0001790340-23-000046.json","markdown":"https://secwatch.observer/filing/0001790340-23-000046.md","text":"https://secwatch.observer/filing/0001790340-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000046/0001790340-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000046/imrx-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:04:49.755982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"526183d10d487c0689ad9edbdedd3a5174b61e5b","claim":"Immuneering Corp reported the second quarter ended June 30, 2023 results: net income $12.2 million, or $0.43 per share, EPS $0.43 per share.","evidence_excerpt":"Net loss attributable to common stockholders was $12.2 million, or $0.43 per share, for the quarter ended June 30, 2023, compared to $11.5 million, or $0.44 per share, for the quarter ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000046/0001790340-23-000046-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$12.2 million, or $0.43 per share"},{"label":"EPS","value":"$0.43 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}